One-Time eye injection could slow blindness in retinitis pigmentosa

NCT ID NCT05748873

Ongoing Disease control Sponsor: SparingVision Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tests a gene therapy called SPVN06 for retinitis pigmentosa, an inherited eye disease that causes gradual vision loss. The treatment is given as a single injection under the retina. The trial includes 33 adults with advanced disease and will check safety and whether it can slow vision decline over up to 5 years.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SPVN06 gene therapy (a single injection under the retina)
What this could lead to: If it works, this could slow or stop vision loss in people with retinitis pigmentosa, preserving sight for years.
What could go wrong: This is an early-phase trial with only 33 people, so success is not guaranteed. The injection itself carries risks like infection or retinal damage, and the therapy may not work for all genetic types.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RETINITIS PIGMENTOSA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cone-rod dystrophy eye disorder inherited retinal dystrophy retinal degeneration retinal disorder retinitis pigmentosa

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RETINITIS PIGMENTOSA

Contacts and locations

Locations

Bascom Palmer Eye Institute/University of Miami

Miami, Florida, 33136, United States
CHNO XV-XX Paris - CIC 1423

Paris, 75012, France
Casey Eye Institute

Portland, Oregon, 97239, United States
Mass Eye and Ear

Boston, Massachusetts, 02114, United States
Retina Foundation of the Southwest

Dallas, Texas, 75231, United States
UPMC Eye Center

Pittsburgh, Pennsylvania, 15213, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.